<DOC>
	<DOCNO>NCT01963130</DOCNO>
	<brief_summary>This study investigate vildagliptin ( di-peptidyl peptidase 4 inhibitor ) affect portal vein pressure hepatosteatosis patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus ? A Cross Sectional Study</brief_title>
	<detailed_description>Group 1 use metformin ( 1000 mg bid ) gliclazide ( 60 mg qd ) ; Group 2 use amount metformin gliclazide , addition vildagliptin ( 50 mg bid ) . The patient prospectively assign two group purpose study . Using Doppler ultrasound , case measure portal vein flow velocity , portal vein flow portal vein diameter . Degree hepatosteatosis also record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>type 2 DM case least 3 month use drug ( metformin gliclazide metformin gliclazide vildagliptin ) use alcohol cigarette chronic liver disease , chronic renal failure , active infection patient use certain drug may affect portal pressure propronalol , calcium channel blocker , angiotensinconverting enzyme inhibitor , angiotensin receptor blocker isosorbit monohydrate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Portal Vein Pressure</keyword>
	<keyword>Hepatosteatosis</keyword>
</DOC>